Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 52-Week High at $19.87

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) shares reached a new 52-week high on Thursday . The stock traded as high as $19.87 and last traded at $19.83, with a volume of 1107656 shares trading hands. The stock had previously closed at $19.24.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on CPRX shares. HC Wainwright upped their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, June 6th. Truist Financial lifted their target price on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Citigroup upped their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $29.50.

Catalyst Pharmaceuticals Stock Performance

The company has a 50-day moving average price of $16.50 and a 200-day moving average price of $15.77. The firm has a market capitalization of $2.35 billion, a P/E ratio of 36.80 and a beta of 0.70.

Insiders Place Their Bets

In related news, CEO Richard J. Daly sold 17,323 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $15.97, for a total transaction of $276,648.31. Following the completion of the transaction, the chief executive officer now owns 234,824 shares in the company, valued at $3,750,139.28. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Richard J. Daly sold 17,323 shares of the firm’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $15.97, for a total transaction of $276,648.31. Following the sale, the chief executive officer now owns 234,824 shares of the company’s stock, valued at approximately $3,750,139.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Carmen Jeffrey Del sold 36,058 shares of Catalyst Pharmaceuticals stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $18.42, for a total value of $664,188.36. Following the transaction, the insider now owns 12,369 shares in the company, valued at $227,836.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 146,255 shares of company stock worth $2,441,748. Insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in CPRX. Pacer Advisors Inc. boosted its position in shares of Catalyst Pharmaceuticals by 130,918.8% during the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock worth $45,968,000 after buying an additional 2,965,310 shares during the period. Janus Henderson Group PLC lifted its position in Catalyst Pharmaceuticals by 139.5% during the 1st quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock worth $43,445,000 after buying an additional 1,587,794 shares in the last quarter. Boston Partners boosted its stake in shares of Catalyst Pharmaceuticals by 965.2% during the 4th quarter. Boston Partners now owns 1,541,660 shares of the biopharmaceutical company’s stock worth $25,610,000 after buying an additional 1,396,930 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after buying an additional 860,244 shares during the last quarter. Finally, Mesirow Institutional Investment Management Inc. bought a new position in shares of Catalyst Pharmaceuticals in the 1st quarter valued at about $11,463,000. Institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.